Chemomab Therapeutics Ltd.
CMMBHealthcare|Biotechnology|IL
$1.32
+0.07 (+5.60%)
DCF Value
$1.56
Tangible Book / Share
$1.09
Cash / Share
$0.84
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06210945 Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis | Systemic Sclerosis | P2 | SUSPENDED | 45 | RCT, Double-blind | 10 mg/kg CM-101, Placebo |
| NCT04595825 CM-101 in PSC Patients -The SPRING Study | Primary Sclerosing Cholangitis | P2 | Completed | 77 | RCT, Double-blind | Anti-human CCL24 monoclonal antibody (CM-101) |
| NCT05824156 CM-101 in NASH Patients - The SPLASH Study | Nonalcoholic Steatohepatitis | P2 | Completed | 23 | RCT, Double-blind | 5 mg/kg CM-101 |
| NCT06044467 The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects | Nonalcoholic Fatty Liver Disease | P1 | Completed | 16 | RCT, Double-blind | Anti-human CCL24 monoclonal antibody (CM-101) - Part One, Anti-human CCL24 monoclonal antibody (CM-101) - Part Two, Placebo - Study Part One, Placebo - Study Part Two |
| NCT06025851 Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects | Healthy | P1 | Completed | 32 | RCT, Double-blind | Anti-human CCL24 monoclonal antibody (CM-101), Placebo |
| NCT06037577 Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects | Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | P1 | Completed | 8 | RCT, Double-blind | CM-101, Placebo |